blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2081602

EP2081602 - TOXIN PEPTIDE THERAPEUTIC AGENTS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  18.05.2012
Database last updated on 10.03.2026
Most recent event   Tooltip18.05.2012Application deemed to be withdrawnpublished on 20.06.2012  [2012/25]
Applicant(s)For all designated states
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 / US
[2009/31]
Inventor(s)01 / SULLIVAN, John, K.
1085 Rotella Street
Newbury Park, CA 91320 / US
02 / MCGIVERN, Joseph, G.
6208 Normandy Terrace
Oak Park, CA 91377 / US
03 / MIRANDA, Leslie, P.
3586 Mapleknoll Place
Thousand Oaks, CA 91362 / US
04 / NGUYEN, Hung, Q.
400 Paseo Camarillo, 212
Camarillo, California 93010 / US
05 / WALKER, Kenneth, W.
175 Mesa Avenue
Newbury Park, CA 91320 / US
06 / HU, Shaw-Fen, Sylvia
986 Lynnmere Drive
Thousand Oaks, CA 91360 / US
07 / GEGG, Colin, V., Jr.
736 Kenmore Circle
Newbury Park, CA 91320 / US
08 / ARORA KHARE, Taruna
5380 Via Pisa
Thousand Oaks, CA 91320 / US
09 / ADLER, Beverly, S.
206 Anne Court
Newbury Park, CA 91320 / US
10 / MARTIN, Francis, H.
865 Fernhill Court
Newbury Park, CA 91320 / US
 [2009/43]
Former [2009/31]01 / SULLIVAN, John, K.
1085 Rotella Street
Newbury Park, CA 91320 / US
02 / MCGIVERN, Joseph, G.
6208 Normandy Terrace
Oak Park, CA 91377 / US
03 / MIRANDA, Leslie, P.
3586 Mapleknoll Place
Thousand Oaks, CA 91362 / US
04 / NGUYEN, Hung, Q.
881 Saint Charles Drive, Apt. 10
Thousand Oaks, CA 91360 / US
05 / WALKER, Kenneth, W.
175 Mesa Avenue
Newbury Park, CA 91320 / US
06 / HU, Shaw-Fen, Sylvia
986 Lynnmere Drive
Thousand Oaks, CA 91360 / US
07 / GEGG, Colin, V., Jr.
736 Kenmore Circle
Newbury Park, CA 91320 / US
08 / ARORA KHARE, Taruna
5380 Via Pisa
Thousand Oaks, CA 91320 / US
09 / ADLER, Beverly, S.
206 Anne Court
Newbury Park, CA 91320 / US
10 / MARTIN, Francis, H.
865 Fernhill Court
Newbury Park, CA 91320 / US
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstrasse 4
80802 München / DE
[N/P]
Former [2009/31]Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät
Leopoldstrasse 4
80802 München / DE
Application number, filing date07872190.925.10.2007
[2009/31]
WO2007US22831
Priority number, dateUS20060854674P25.10.2006         Original published format: US 854674 P
US20070995370P25.09.2007         Original published format: US 995370 P
[2009/31]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008088422
Date:24.07.2008
Language:EN
[2008/30]
Type: A2 Application without search report 
No.:EP2081602
Date:29.07.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 24.07.2008 takes the place of the publication of the European patent application.
[2009/31]
Search report(s)International search report - published on:EP19.02.2009
ClassificationIPC:A61K47/48
[2009/31]
CPC:
C07K14/43522 (EP,US); A61K47/60 (EP,US); A61P29/00 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P37/06 (EP);
A61P43/00 (EP); A61K38/00 (EP,US); C07K2319/30 (EP,US);
C07K2319/31 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/31]
TitleGerman:THERAPEUTISCHE TOXINPEPTID-MITTEL[2009/31]
English:TOXIN PEPTIDE THERAPEUTIC AGENTS[2009/31]
French:AGENTS THÉRAPEUTIQUES À BASE DE PEPTIDES TOXIQUES[2009/31]
Entry into regional phase15.05.2009National basic fee paid 
15.05.2009Designation fee(s) paid 
15.05.2009Examination fee paid 
Examination procedure20.08.2008Request for preliminary examination filed
International Preliminary Examining Authority: EP
15.05.2009Amendment by applicant (claims and/or description)
15.05.2009Examination requested  [2009/31]
10.08.2010Despatch of a communication from the examining division (Time limit: M04)
17.12.2010Reply to a communication from the examining division
16.08.2011Despatch of a communication from the examining division (Time limit: M04)
28.12.2011Application deemed to be withdrawn, date of legal effect  [2012/25]
02.02.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2012/25]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  10.08.2010
Fees paidRenewal fee
13.10.2009Renewal fee patent year 03
12.10.2010Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.10.201105   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]   TYTGAT J ET AL: "A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 20, no. 11, 1 November 1999 (1999-11-01), pages 444 - 447, XP004182937, ISSN: 0165-6147 [A] * the whole document *

DOI:   http://dx.doi.org/10.1016/S0165-6147(99)01398-X
 [A]   JUDGE ET AL: "Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 111, no. 1, 1 July 2006 (2006-07-01), pages 224 - 259, XP005451102, ISSN: 0163-7258 [A] * the whole document *
 [L]   MOUHAT S ET AL: "K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, vol. 385, no. Part 1, 1 January 2005 (2005-01-01), pages 95 - 104, XP002352829, ISSN: 0264-6021 [L] * the whole document *

DOI:   http://dx.doi.org/10.1042/BJ20041379
 [A]   BEDNAREK MARIA A ET AL: "Chemical synthesis and structure-function studies of margatoxin, a potent inhibitor of voltage-dependent potassium channel in human T lymphocytes", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 198, no. 2, 1994, pages 619 - 625, XP002492920, ISSN: 0006-291X [A] * the whole document *

DOI:   http://dx.doi.org/10.1006/bbrc.1994.1090
 [A]   LEGROS C ET AL: "Influence of a NH2-terminal extension on the activity of KTX2, a K<+> channel blocker purified from Androctonus australis scorpion venom", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 417, no. 1, 3 November 1997 (1997-11-03), pages 123 - 129, XP004261406, ISSN: 0014-5793 [A] * the whole document *

DOI:   http://dx.doi.org/10.1016/S0014-5793(97)01177-0
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.